Location History:
- Saitama, JP (1982)
- Kuki, JP (1987 - 1990)
Company Filing History:
Years Active: 1982-1990
Title: Akira Onodera: Innovator in Cephalosporin Derivatives
Introduction
Akira Onodera is a notable inventor based in Kuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cephalosporin derivatives. With a total of 6 patents to his name, Onodera's work has had a substantial impact on antibacterial agents.
Latest Patents
Onodera's latest patents include innovative cephalosporin derivatives. One of his notable inventions is a cephalosporin derivative represented by a specific general formula, wherein R¹ is a hydrogen atom or a protecting group of the amino group, R² is a hydrogen atom or a protecting group of the hydroxyl group, R³ is a hydrogen atom or a protecting group of the carboxyl group, and R⁴ is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. These compounds, along with their non-toxic salts, are useful as antibacterial agents. Another patent describes a cephalosporin derivative where R¹, R², and R³ have similar definitions, while X can be a halogen atom, a cyano group, a vinyl group, a lower alkoxy group, or a lower alkylthio group. This invention also emphasizes the potential of these compounds as effective antibacterial agents for oral administration.
Career Highlights
Onodera is currently associated with Taisho Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the development of new antibacterial treatments.
Collaborations
Onodera has collaborated with several talented individuals in his field, including Yoshiaki Watanabe and Chihiro Yokoo, who is a prominent female researcher. Their combined efforts have contributed to the success of various projects and patents.
Conclusion
Akira Onodera's contributions to the field of cephalosporin derivatives highlight his innovative spirit and dedication to improving healthcare. His work continues to influence the development of effective antibacterial agents, showcasing the importance of research and collaboration in the pharmaceutical industry.